Edward Via College of Osteopathic Medicine, Auburn, AL, USA.
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, FL, USA.
J Dermatolog Treat. 2022 May;33(3):1252-1256. doi: 10.1080/09546634.2020.1826394. Epub 2020 Sep 24.
This review article aims to compare global dermatologic organizations and the clinical practice guidelines available for the use of interleukin (IL)-23 inhibitors in the treatment of psoriasis.
A literature review encompassing systemic therapies for the treatment of psoriasis was conducted. Guidelines from the American Academy of Dermatology (AAD)-National Psoriasis Foundation (NPF), the National Institute for Health and Care Excellence (NICE), and the British Association of Dermatologists (BAD) served as the main comparators in this review.
Of the American and European guidelines available for use of IL-23 inhibitors, several organizations are in agreement regarding the dosage and indications of guselkumab, tildrakizumab, and risankizumab. However, there are differences as well as insufficient recommendations concerning laboratory monitoring and screenings as well as contraindications to therapy.
IL-23 inhibitors are safe and efficacious therapeutic options for patients with psoriasis and should be considered as a potential first-line therapy alone or in combination with topical medications, phototherapy, and other systemic non-biologic agents. Consideration should be given to the evidence-based guidelines of global dermatologic organizations to help guide therapeutic decisions.
本文旨在比较全球皮肤科组织和现有的白细胞介素（IL）-23 抑制剂治疗银屑病的临床实践指南。
对治疗银屑病的全身治疗进行了文献回顾。美国皮肤病学会（AAD）-国家银屑病基金会（NPF）、英国国家卫生与保健优化研究所（NICE）和英国皮肤病学会（BAD）的指南是本综述的主要比较标准。
对于现有的 IL-23 抑制剂的美国和欧洲指南，有几个组织在古塞库单抗、替西单抗和瑞莎珠单抗的剂量和适应证方面达成一致。然而，在实验室监测和筛查以及治疗禁忌方面也存在差异和不充分的建议。
IL-23 抑制剂是治疗银屑病患者的安全有效的治疗选择，应考虑将其作为单独或与局部药物、光疗和其他非生物全身药物联合治疗的潜在一线治疗药物。应考虑参考全球皮肤科组织的循证指南，以帮助指导治疗决策。
